// App-Quantinova.ai

5519 : Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

Researchers

Presenter

  • Rachel N. Grisham

Principal Investigators

  • Susana N. Banerjee

  • Esther N. Drill

  • Michel Fabbro

  • Mansoor Raza Mirza

  • Ignacio Romero

  • Robert L. Coleman

  • Amit M. Oza

  • Felix Hilpert

  • Kathleen N. Moore

  • Anneke M. Westermann

  • Carol Aghajanian

  • Giovanni Scambia

  • Adam P. Boyd

  • Jean Cantey-Kiser

  • David M. O'Malley

  • John H. Farley

  • Nicoletta Colombo

  • Bradley J. Monk

Medical Centers

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute, Leuven, Belgium

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • CRLC Val d'Aurelle, Montpellier, France

  • The Finsen Centre 5073, Copenhagen, Denmark

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • US Oncology Research, The Woodlands, TX

  • Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

  • Canada.

  • Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany

  • Stephenson Cancer Center, Oklahoma City, OK

  • VU University Medical Center, Amsterdam, Netherlands

  • Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

  • Array BioPharma, Boulder, CO

  • Biostatistics, PharPoint Research Inc, Durham, NC

  • The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, OH

  • St Joseph's Hospital and Medical Center, a Member of Catholic Healthcare West, Phoenix, AZ

  • University of Milano-Bicocca and European Institute of Oncology, Milano, Italy

  • Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Phoenix, AZ

Locations

  • United States

  • Belgium

  • United Kingdom

  • France

  • Denmark

  • Spain

  • Canada

  • Germany

  • Netherlands

  • Italy

Companies

  • Array BioPharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Genetic Disorder

Disease

  • Gynaecological cancer

Biomarkers

  • N/A

Drug/Treatment

  • Binimetinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01849874

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved